Clinical trials: Dopamine Receptor Occupancy
Schizophrenia
A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls
The primary objective of this study is to compare the effect of two different antipsychotic compounds which are used in the treatment of schizophrenia (paliperidone ER and risperidone) at their target sites in two specific areas…
- Trial name
- NCT00934635
- Testing
- Paliperidone ER, Oral risperidone, PET Scan
- Where
- Germany
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag G.m.b.H
Schizophrenia
SPECT Study With SB-773812 In Schizophrenic Patients
This study is being conducted in 2 groups of schizophrenic patients: in group 1 the relationship between the dopaminergic D2 receptor occupancy (D2 RO ) and serotoninergic 5HT2A receptor occupancy at stable plasma concentration…
- Trial name
- NCT00269035
- Testing
- SB773812, Risperidone
- Where
- 6 sites in Spain
- Volunteers
- 95 people
- Sponsor
- GlaxoSmithKline
Schizophrenia
Predicting Antipsychotic Discontinuation in Psychosis
The purpose of this study is to determine whether dopamine synthesis capacity by using [18 fluorine(F)]-DOPA PET for patients with schizophrenia in the maintenance phase can predict treatment discontinuation.
- Trial name
- PADP (NCT02884518)
- Testing
- PET, clinical scale
- Where
- South Korea
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Schizophrenia Disorder
A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398
This is an open label study in 2 cohorts of healthy volunteers and 1 cohort of patients with Schizophrenia, designed to evaluate the Dopamine D2 and D3 Receptor Occupancy by SIPI6398 at various doses and timepoints.
- Trial name
- NCT07626034
- Testing
- SIPI6398 Tablets
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongze Therapeutics Co., Ltd.
Healthy Volunteers
An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects
The specific aim of this study is to document the pharmacokinetics of DAT receptor occupancy of OROS and immediate release (IR) MPH using PET scanning with C-11 altropane as the ligand.
- Trial name
- NCT00302367
- Testing
- OROS methylphenidate hydrochloride, immediate release methylphenidate hydrochloride
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700
The purpose of this PET study is to verify the binding of Lu AF35700 after multiple oral dosing at the dopamine and the serotonin receptors in male patients with schizophrenia.
- Trial name
- NCT02333487
- Testing
- Lu AF35700
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers
This is an open label study in 4 cohort of 4 healthy volunteers each designed to evaluate the dopamine receptor occupancy of LB-102 at various doses and timepoints.
- Trial name
- NCT04588129
- Testing
- LB-102
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- LB Pharmaceuticals Inc.
D3 Dopamine Receptor, Cocaine-dependent
Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT
Preclinical work suggests that D3 dopamine receptors may be important in the study of the pathophysiology of affective disorders, psychotic disorders and addiction.
- Conditions
- D3 Dopamine Receptor, Cocaine-dependent, Healthy Volunteer
- Trial name
- NCT02815917
- Testing
- [18F]FTP PET/CT
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Bipolar Depression
Dopamine D3 Receptor Occupancy in Bipolar Depression
Bipolar disorder is a common condition that can cause significant disability and risk for suicide. Second generation antipsychotic medications can be used to treat depression in bipolar disorder, yet we do not know how they work.
- Trial name
- NCT05060549
- Testing
- Cariprazine
- Where
- United States
- Sponsor
- New York State Psychiatric Institute
Healthy Men
D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound
To investigate the relationship between the combined Lu AF35700 and Lu AF36152 plasma concentration and D2 dopamine receptor occupancy up to 172 hours after oral dosing of Lu AF35700
- Trial name
- NCT02093169
- Testing
- Part A: Lu AF35700, Part B: Lu AF35700
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Schizophrenia
[18 Fluorine(F)]DOPA Determinants and Predictors of Treatment Response in Psychosis
The first purpose of this study is to determine if dopamine synthesis capacity is significantly lower in treatment non-responders from illness onset relative to treatment responders.
- Trial name
- DPTP (NCT02880995)
- Testing
- PET scan, clinical scale, 6 weeks of treatment with amisulpride
- Where
- 2 sites in South Korea
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Drug Binding to DAT Receptors
Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate
The objectives of this study are to document the pharmacokinetics of the adequacy of DAT receptor occupancy d-MPH formulation in three doses (20 mg, 30 mg, and 40 mg) using PET scanning with C-11 Altropane as the ligand across a…
- Trial name
- NCT00593138
- Testing
- dex-methylphenidate
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Schizophrenia
A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS Paliperidone
The purposes of this study are to estimate the relationship of D2-receptor occupancy to plasma concentration and to assess the safety of OROS paliperidone.
- Trial name
- NCT00796432
- Testing
- OROS paliperidone
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depression
Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL
The aim of this study is to relate pharmacokinetics of two different formulations of quetiapine to PET measured receptor occupancy in the brains of healthy subjects.
- Trial name
- PET (NCT00832221)
- Testing
- SEROQUEL XR (quetiapine), SEROQUEL IR (quetiapine), radioligand [11C]raclopride
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Subjects
Study of Safety, Blood Levels and Brain Receptor Occupancy of GSK598809 Using PET Imaging in Health Males.
The purpose of this study is to look at how much of a new drug, GSK598809 binds to specific proteins in the brain and how much stays in the blood over a range of different doses.
- Trial name
- NCT00468806
- Testing
- GSK598809, using [11C]-(+)-PHNO
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Substance Dependence
An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand
The purpose of this study is to investigate the relationship between the plasma concentrations of the study drug and the amount of the study drug bound to the D3 receptors of the brain after dosing of a new compound GSK618334.
- Trial name
- NCT00814957
- Testing
- GSK618334
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults
The specific aim of this study is to document the pharmacokinetics of dopamine transporter DAT receptor occupancy of OROS MPH and Metadate CD using PET scanning with C-11 Altropane as the ligand.
- Trial name
- NCT00301639
- Testing
- OROS methylphenidate hydrochloride, methylphenidate hydrochloride
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Smoking
PET Imaging Study on Occupancy of Dopamine D2 Receptors and Genotypes After Bupropion Administration
Bupropion has different effects on D2 dopamine receptors according to genotype.
- Trial name
- NCT00846339
- Testing
- Bupropion
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Seoul National University Hospital
Dopamine Receptor Occupancy, Medication Satisfaction
Validation of Receptor Occupancy Simulation
To estimate dopamine receptor occupancy by aripiprazole using computer simulation To measure dopamine receptor occupancy by aripiprazole in patients treated with the antipsychotics To validate the simulation result by comparing…
- Conditions
- Dopamine Receptor Occupancy, Medication Satisfaction, Prolactin Level, Schizophrenia
- Trial name
- NCT01660880
- Where
- South Korea
- Volunteers
- 7 people
- Sponsor
- Seoul National University Hospital
Healthy
Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults
There are two specific aims of this study. The first is to document the pharmacokinetics of dopamine transporter (DAT) receptor occupancy of repeated administration of orally administered, therapeutic doses of a short immediate…
- Trial name
- NCT00302393
- Testing
- OROS methylphenidate hydrochloride, methylphenidate hydrochloride
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital